Compounds > sulfasalazine
Page last updated: 2024-08-16

sulfasalazine and gemcitabine

sulfasalazine has been researched along with gemcitabine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Arlt, A; Fölsch, UR; Gehrz, A; Grohmann, F; Haye, S; Kalthoff, H; March, C; Müerköster, S; Schäfer, H; Wegehenkel, K; Witt, M1
Appelbaum, L; Breuer, S; Hubert, A; Maimon, O; Peretz, T1
Abramovitch, R; Corchia, N; Dery, E; Fried, I; Gross, E; Komar-Stossel, C; Meir, K1

Reviews

1 review(s) available for sulfasalazine and gemcitabine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for sulfasalazine and gemcitabine

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer.
    International journal of cancer, 2003, Apr-20, Volume: 104, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Sulfasalazine; Tumor Cells, Cultured

2003
TL-118-anti-angiogenic treatment in pancreatic cancer: a case report.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Cyclophosphamide; Deoxycytidine; Diclofenac; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Sulfasalazine; Tomography, X-Ray Computed

2013
TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cimetidine; Cyclophosphamide; Deoxycytidine; Diclofenac; Drug Administration Schedule; Drug Combinations; Drug Synergism; Gemcitabine; Gene Amplification; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Mice, Inbred NOD; Mice, SCID; N-Myc Proto-Oncogene Protein; Neovascularization, Pathologic; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Platelet Endothelial Cell Adhesion Molecule-1; Sulfasalazine; Treatment Outcome; Tretinoin; Tumor Burden; Xenograft Model Antitumor Assays

2014